This study characterizes HPN328, a trispecific T cell–activating construct (TriTAC) designed to engage T cells via CD3, bind to DLL3 on tumor cells, and extend half-life through albumin binding. Preclinical evaluations demonstrated potent, dose-dependent cytotoxicity against DLL3-expressing small cell lung cancer (SCLC) cell lines, with concomitant T cell activation and cytokine release. In vivo studies using immunocompetent mice expressing human CD3ε showed significant tumor regression and long-term immunity upon tumor rechallenge.
HPN328 effectively redirects T cells to kill DLL3-expressing tumor cells, demonstrating robust antitumor activity and inducing long-term immune memory in humanized CD3ε mouse models.
Humanized CD3ε Knockin mouse model developed by genOway, enabling assessment of T cell engagers targeting human CD3 in an immunocompetent setting.
Immuno-oncology, T cell engagers, Small cell lung cancer, DLL3 targeting, Trispecific antibodies
Humanized Knockin, CD3ε, Immunocompetent mouse model, T cell engager evaluation
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
